Steve Uden has led Alexion Research since joining the company 2 years ago. Alexion Research focuses on the discovery of novel therapies that have a transformative impact on patients with devastating and rare disease. As a result the group takes an agnostic position on which diseases to research as their primary focus is transformative benefit rather than a therapeutic area focus. In order to achieve this goal the group has the capability to bring the best therapeutic modality to bear in developing new drugs utilizing their internal expertise in antibody and protein engineering or through partnerships with other companies to gain access to modalities such as small molecules, peptides or RNA therapies.
Prior to joining Alexion, Steve was the Head of Oncology Development for Novartis Pharma in Japan.. There he participated in a series of global programs that led to four oncology drug approvals in Japan during his time there. Previously, Steve served as VP and Head of R&D for Wyeth Japan – administering a full spectrum of R&D activities and strategies in Asia Pacific across all of Wyeth’s therapeutic areas. Earlier in his career, Steve held leadership roles in several biopharmaceutical companies, including Head of R&D at Neurogen Corp., where he oversaw target selection through clinical development, and supported new business strategy.
Steve earned his Bachelor of Medicine and Bachelor of Science from St. Thomas Medical School, University of London, as well as membership in the Royal College of Physicians and Faculty of Pharmaceutical Medicine.